Concurrent SF3B1 Mutation and BCR::ABL1 Demonstrating a Myelodysplastic Syndrome Phenotype: A Case Report [0.03%]
SF3B1突变和BCR::ABL1共存并表现出骨髓增生异常综合征表型的病例报告
Eugene Brailovski,Amirali Vahedi,Véronique Lisi et al.
Eugene Brailovski et al.
Chronic myeloid leukemia (CML) is a myeloproliferative disorder caused by the BCR::ABL1 translocation and usually presents with leukocytosis. While somatic mutations can occasionally occur within CML, co-mutations in SF3B1 have rarely been ...
Adding Bortezomib and Bendamustine to High-Dose Melphalan in Autologous Haematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma-A Single Centre Retrospective Study [0.03%]
硼替佐米和苯达莫司汀联合大剂量美法仑在自体造血干细胞移植治疗复发性多发性骨髓瘤中的应用——单中心回顾研究
Thomas Silfverberg,Honar Cherif,Emma Smitt et al.
Thomas Silfverberg et al.
Introduction: High-dose melphalan (HDM) followed by autologous haematopoietic stem cell transplantation (ASCT) remains the standard of care for eligible patients with multiple myeloma (MM). Our objective was to evaluate t...
Reciprocal Clonal Dynamics of Independent FLT3 D835V-Positive Acute Myeloid Leukemia and Chronic Myeloid Leukemia With Gilteritinib [0.03%]
FLT3 D835V阳性急性髓系白血病与慢性粒细胞白血病的克隆互为动态以及吉列替尼治疗
Kai Osone,Seiichiro Katagiri,SungGi Chi et al.
Kai Osone et al.
We report a 65-year-old man with FLT3 D835V-mutated acute myeloid leukemia (AML) and BCR::ABL1-positive chronic myeloid leukemia (CML) that coexisted as genetically independent clones. Cytogenetic and targeted sequencing analyses demonstrat...
Splenic B-Cell Lymphoma/Leukemia With Prominent Nucleoli Presenting With Characteristic Peripheral Blood and Bone Marrow Findings [0.03%]
具有显著核仁的脾B细胞淋巴瘤/白血病伴外周血和骨髓特征性表现
Koie Son,Yoshimitsu Shimomura,Daisuke Yamashita et al.
Koie Son et al.
Durable Remission of Highly Refractory Multiple Myeloma and Therapy-Related MDS/AML After Allogeneic Hematopoietic Cell Transplantation: Reconsidering Its Role in the CAR-T Era [0.03%]
异基因造血细胞移植治疗难治多发性骨髓瘤和CAR-T时代的移植物抗白血病效应:一例伴治疗相关MDS/AML患者的长期缓解报告
Tomoko Kumamoto,Kyoko Yoshihara,Mami Samori et al.
Tomoko Kumamoto et al.
Therapy-related myelodysplastic syndrome and acute myeloid leukemia (MDS/AML) are increasingly recognized as late complications of multiple myeloma (MM) treatment and are associated with a dismal prognosis. We report on a patient with highl...
Identification of an Elusive CBFA2T3::GLIS2 Fusion Variant in Acute Megakaryoblastic Leukemia by Whole Genome Sequencing [0.03%]
急性巨核细胞白血病中超罕见的CBFA2T3::GLIS2融合变异的鉴定:全基因组测序技术
Yuna Lee,Jung Yoon Choi,Hyun Jin Park et al.
Yuna Lee et al.
Advancements in genomic profiling have significantly improved the classification and treatment strategies for acute myeloid leukemia (AML). However, widely utilized molecular diagnostic techniques, including targeted gene panels, are often ...
Giovanni Barosi,Vittorio Rosti,Robert P Gale
Giovanni Barosi
Treatment Discontinuation After Achieving MRD Negativity in Multiple Myeloma in the Pre-BCMA Era: A Prospective, Single-Centre Study [0.03%]
靶向BCMA时代之前MM患者实现MRD阴性后的治疗中断:一项前瞻性单中心研究
Kota Sato,Kenshi Suzuki,Shotaro Sugita et al.
Kota Sato et al.
Objectives: Minimal/measurable residual disease (MRD) negativity in multiple myeloma (MM) is associated with favourable outcomes; nonetheless, evidence supporting treatment discontinuation remains limited. We evaluated th...
Paroxysmal Nocturnal Haemoglobinuria-Associated Acute Cutaneous Thrombosis and Haemolysis in the Setting of Parvovirus B19 and Varicella Zoster Virus Infection [0.03%]
与B19型细小病毒及带状疱疹病毒感染相关的阵发性夜间血红蛋白尿急性皮肤血栓形成和溶血病例
Louise J Potter,Roochi Trikha,Shreyans Gandhi et al.
Louise J Potter et al.
A 28-year-old male with paroxysmal nocturnal haemoglobinuria (PNH) presented with headache, nasal bridge discomfort and haemoglobinuria. He developed a macular-papular rash which rapidly progressed into purpura, necrosis and peri-orbital oe...
Successful Treatment of Aplastic Anemia With Eltrombopag During Pregnancy: A Short Report [0.03%]
艾曲波帕治疗孕期再生障碍性贫血1例报告
Sandra M Frey,Ferras Alashkar,H Christian Reinhardt et al.
Sandra M Frey et al.
Introduction: Aplastic anemia (AA) is a rare bone marrow failure syndrome with pancytopenia, mainly due to immune-mediated stem cell destruction. First-line therapy for acquired severe AA ≥ 50 years/non-severe AA (NSAA) ...